⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

March 31, 2026Scandinavian Journal of Gastroenterology

Evaluation of pegylated interferon-α therapy efficacy in patients with inactive hepatitis B surface antigen carrier state

Haiyi Cai Lifen Zhu Pei Zhou Rui Li Xiaoping Tang YuJuan Guan Yaping Wang

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to evaluate the efficacy of pegylated interferon-α therapy in patients with inactive hepatitis B surface antigen carrier state.
Evaluation of therapeutic benefits of PegIFNα-2b therapy
Comparison of outcomes based on baseline HBsAg levels
Analysis of HBV management strategies
PegIFNα-2b shows therapeutic benefits in patients with inactive hepatitis B
Lower baseline HBsAg levels correlate with better outcomes
Suggests incorporation into broader HBV management strategies

Implication

Evaluation of pegylated interferon improves outcomes in inactive hepatitis B carriers, suggesting new management strategies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Cai et al. (2026) studied this question.

synapsesocial.com/papers/69cf5cb15a333a821460a3f3 https://doi.org/10.1080/00365521.2026.2652011

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Pegylated Interferon Treatment for the Effective Clearance of Hepatitis B Surface Antigen in Inactive HBsAg Carriers: A Meta-AnalysisMeta-Analysis · 2021 · 34 citations
2Alpha-interferon treatment in hepatitis BOriginal Research · 2017 · 87 citations
3Short-term pegylated interferon alpha in chronic HBV patients with ultra-low HBsAg: a retrospective study2025 · 3 citations
4Hepatitis B surface antigen clearance rate with pegylated interferon-α therapy in different chronic hepatitis B virus infection populations: A systematic review and meta-analysisMeta-Analysis · 2026
5Incidence and predictors of HBsAg loss following addition of pegylated interferon Alfa-2b in chronic hepatitis B patients suppressed by nucleos(t)ide analogues: a multicenter, prospective, cohort studyCohort Study · 2026 · 1 citations